MARKET

TLGT

TLGT

Teligent Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.8240
-0.0909
-9.94%
Pre Market: 0.7800 -0.044 -5.34% 07:50 03/04 EST
OPEN
0.9075
PREV CLOSE
0.9149
HIGH
0.9164
LOW
0.8221
VOLUME
24.43K
TURNOVER
--
52 WEEK HIGH
6.46
52 WEEK LOW
0.4550
MARKET CAP
55.61M
P/E (TTM)
-0.0957
1D
5D
1M
3M
1Y
5Y
Erythromycin Market 2021 : Top countries Data, Market Size, In-Depth Analysis with Booming Trends and Segmentation Forecast to 2026
Feb 25, 2021 (The Expresswire) -- According to 360 Research Reports, the “Erythromycin Market" 2021 by Types (Gel, Tablet, Topical Solution, Ointment,...
The Express Wire · 02/25 07:52
Top Penny Stocks To Buy Now? 4 To Watch Today
Feb 24, 2021 (Penny Stocks via COMTEX) -- Monday, February 8th, marked a new week for penny stocks. Overall, the stock market saw a large bullish jump...
Penny Stocks · 02/24 21:11
Lidocaine Ointment Market Size 2021 by Revenue Estimates, Capacity, Price, Gross Margin and Forecast to 2027 Research Report by Absolute Reports
Feb 24, 2021 (The Expresswire) -- "Final Report will add the analysis of the impact of COVID-19 on this industry." “Lidocaine Ointment Market” research...
The Express Wire · 02/24 09:20
Triamcinolone Market Analysis, Recent Trends & Development, Top Company Profiles & Forecast 2020-2027 By Ameco Research
pune, India, Wed, 24 Feb 2021 01:06:28 / Comserve Inc. / -- The global Triamcinolone market size is projected to reach US$ 864.6 million by 2027, from US$...
Comserve · 02/24 06:07
8-K: Teligent, Inc.
Edgar Online - (EDK = 8-Ks/S1/S-4) · 02/23 15:12
BRIEF-Teligent Inc Announces Appointment Of Carter Pate To Board Of Directors
reuters.com · 02/23 12:37
Press Release: Teligent, Inc. Announces Appointment of Carter Pate to Board of Directors
Dow Jones · 02/23 12:30
Econazole Nitrate Cream Market Size, Global Strategic Analysis, Revenue Opportunities, Share, Emerging Technologies, Sales, Revenue, Key Players Analysis, Development Status, Growth, Drivers | Forecast 2021-2027
Feb 22, 2021 (The Expresswire) -- Global "Econazole Nitrate Cream Market" Research Report features an extensive study of the current market landscape and...
The Express Wire · 02/22 07:52
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of TLGT. Analyze the recent business situations of Teligent Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average TLGT stock price target is 1.000 with a high estimate of 1.000 and a low estimate of 1.000.
EPS
Institutional Holdings
Institutions: 79
Institutional Holdings: 14.00M
% Owned: 20.74%
Shares Outstanding: 67.49M
TypeInstitutionsShares
Increased
3
399.64K
New
6
-705.86K
Decreased
4
441.06K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.99%
Pharmaceuticals & Medical Research
-1.89%
Key Executives
Chairman/Director
John Celentano
President/Chief Executive Officer/Director
Timothy Sawyer
Secretary
Philip Yachmetz
Director
William Marth
Director
Carter Pate
Independent Director
Carole Ben-Maimon
Independent Director
Bhaskar Chaudhuri
Independent Director
Steven Koehler
Independent Director
Thomas Sabatino
No Data
About TLGT
Teligent, Inc., formerly Igi Laboratories Inc, is a specialty generic pharmaceutical company. Under the Company's own label, it markets and sells generic injectable pharmaceutical products in the United States and Canada. In the United States it marketed 35 generic topical pharmaceutical products and four branded generic pharmaceutical products, as of December 31, 2018. It provides development, formulation and manufacturing services to the pharmaceutical, over-the-counter (OTC) and cosmetic industries. It focuses on developing, manufacturing and marketing a portfolio of generic pharmaceutical products under its own label in topical, injectable, complex and ophthalmic dosage forms, and managing its contract manufacturing and formulation services business. Its pipeline included 20 Abbreviated New Drug Application (ANDAs) filed with the United States Food and Drug Administration (FDA) for additional pharmaceutical products, as of December 31, 2018.

Webull offers kinds of Teligent Inc (NEW JERSEY) stock information, including NASDAQ:TLGT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TLGT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading TLGT stock methods without spending real money on the virtual paper trading platform.